Welcome to our dedicated page for Royalty Pharma news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma stock.
Royalty Pharma plc reports developments tied to its biopharmaceutical royalty portfolio and life-sciences funding model. The company acquires existing royalties from medicine innovators and enters direct funding arrangements, including co-funding for late-stage clinical trials and product launches, in exchange for future royalties.
Recurring news covers Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, royalty transactions, and updates from commercial products and development-stage candidates. Company announcements also address R&D funding collaborations, portfolio clinical and regulatory developments, leadership additions in partnering and technology, investor conference appearances, and scientific initiatives such as the Royalty Pharma Translational Prize.
Royalty Pharma (Nasdaq: RPRX) has announced the pricing of $2.0 billion in senior unsecured notes across three tranches: $600 million of 4.450% Notes due 2031, $900 million of 5.200% Notes due 2035, and $500 million of 5.950% Notes due 2055.
The notes will be guaranteed by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. The offering is expected to close on September 16, 2025. The company plans to use the proceeds for general corporate purposes. Multiple financial institutions, led by BofA Securities, Goldman Sachs, J.P. Morgan, Morgan Stanley, and TD Securities, are serving as joint book-running managers.
Royalty Pharma (Nasdaq: RPRX) has entered into a significant funding agreement with Zenas BioPharma for up to $300 million in exchange for royalties on obexelimab sales. The deal includes an upfront payment of $75 million and three additional $75 million payments tied to clinical and regulatory milestones.
The funding will support obexelimab's development and potential commercial launch for IgG4-Related Disease (IgG4-RD) in early 2027. Royalty Pharma will receive a 5.5% royalty on worldwide net sales. The drug is currently in Phase 3 trials for IgG4-RD and Phase 2 trials for Multiple Sclerosis and Systemic Lupus Erythematosus, with key trial results expected around year-end.
Royalty Pharma (NASDAQ:RPRX) has announced the acquisition of a royalty interest in Amgen's Imdelltra from BeOne Medicines for $885 million upfront, with an additional $65 million option available to BeOne within 12 months. The deal involves approximately 7% royalty on worldwide net sales of Imdelltra, extending through 2038-2041.
Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), received FDA accelerated approval in May 2024 for treating extensive-stage small cell lung cancer. The drug achieved $215 million in sales during H1 2025 and is projected to reach $2.8 billion by 2035. The agreement includes royalty sharing with BeOne on annual net sales above $1.5 billion, while BeOne retains China commercial rights.
BeOne Medicines (Nasdaq: ONC) has entered into a significant royalty purchase agreement with Royalty Pharma for up to $950 million for IMDELLTRA® worldwide sales rights (excluding China). The deal includes an $885 million upfront payment and a potential additional $65 million within 12 months.
IMDELLTRA® is a groundbreaking DLL-3 targeting bispecific T-cell engager approved for treating extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after platinum-based chemotherapy. BeOne will retain a portion of royalties on annual sales above $1.5 billion and maintain rights to other assets under its Amgen collaboration, including xaluritamig.
Royalty Pharma (NASDAQ:RPRX) announced that Henry Fernandez has stepped down from his position as Lead Independent Director on the company's Board of Directors, effective August 13, 2025. Fernandez joined the board in July 2020 and was appointed Lead Independent Director in March 2021.
During his tenure, Fernandez contributed to several company milestones, including the completion of internalization. CEO Pablo Legorreta praised Fernandez's leadership and business expertise, particularly valuable during Royalty Pharma's early years as a public company. The company plans to appoint a new Lead Independent Director in the near future.
Royalty Pharma (NASDAQ:RPRX) reported strong Q2 2025 results with Portfolio Receipts growing 20% to $727 million and Royalty Receipts increasing 11% to $672 million. The company raised its full-year 2025 guidance, now expecting Portfolio Receipts between $3,050-$3,150 million, representing 9-12% growth.
Key Q2 highlights include the completion of external manager acquisition, a groundbreaking $2 billion funding agreement with Revolution Medicines, and $1 billion in share repurchases during H1 2025. The company maintained strong liquidity with $632 million in cash and $8.2 billion in total debt as of June 30, 2025.
Growth was primarily driven by strong performance from products including Voranigo, Trelegy, Evrysdi, and Tremfya, while positive clinical updates were reported across the portfolio, notably for Gilead's Trodelvy in breast cancer treatment.
Royalty Pharma (Nasdaq: RPRX) has announced its quarterly dividend payment for Q3 2025. The company will distribute a dividend of $0.22 per Class A ordinary share. The dividend is scheduled to be paid on September 10, 2025, to shareholders who are registered as of the record date on August 15, 2025.
Royalty Pharma (NASDAQ:RPRX) has appointed two new independent directors to its Board: Carole Ho, Chief Medical Officer at Denali Therapeutics, and Elizabeth Weatherman, Special Limited Partner at Warburg Pincus. The appointments increase independent board representation to over 90% and follow the company's acquisition of its external manager.
Dr. Ho brings 20 years of biopharma experience, currently leading therapeutic development at Denali and previously serving as Vice President of Clinical Development at Genentech. Weatherman contributes 35 years of healthcare industry investment expertise from her tenure at Warburg Pincus, where she led the Healthcare Group and served on numerous corporate boards.
Royalty Pharma (NASDAQ:RPRX) has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day.
Investors can access the conference call details and live webcast through the company's website at their Investors page. A replay of both the call and webcast will remain available on Royalty Pharma's website for a minimum of 30 days following the event.